S&P 500 Healthcare Sector SPDR (XLV)

As Cardinal Health has outpaced relative to the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook about the stock’s prospects.

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

Abbott has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Michael Burry has chosen to believe in Zoetis’ growth story by increasing his position.

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

Gilead Sciences has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

The high-momentum groups leading us to the upside, like tech and chips, are now withering...while the less-popular, less-exciting names, like consumer staples and health care, are shining.

Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.